These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28529647)

  • 1. Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
    Yang C; Li C; Zhang P; Wu W; Jiang X
    Theranostics; 2017; 7(6):1719-1734. PubMed ID: 28529647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
    Lee H; Mok H; Lee S; Oh YK; Park TG
    J Control Release; 2007 Jun; 119(2):245-52. PubMed ID: 17408798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bio-derived poly(gamma-glutamic acid) nanogels as controlled anticancer drug delivery carriers.
    Bae HH; Cho MY; Hong JH; Poo H; Sung MH; Lim YT
    J Microbiol Biotechnol; 2012 Dec; 22(12):1782-9. PubMed ID: 23221543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
    Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
    Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
    Wei X; Senanayake TH; Warren G; Vinogradov SV
    Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
    Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
    J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
    Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 2 (TLR2), transforming growth factor-β, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis.
    Foley JP; Lam D; Jiang H; Liao J; Cheong N; McDevitt TM; Zaman A; Wright JR; Savani RC
    J Biol Chem; 2012 Oct; 287(44):37406-19. PubMed ID: 22948158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis.
    Minato A; Kudo Y; Noguchi H; Kohi S; Hasegawa Y; Sato N; Hirata K; Fujimoto N
    Cancer Genomics Proteomics; 2023; 20(2):203-210. PubMed ID: 36870687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
    Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
    Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury.
    Cui Z; Liao J; Cheong N; Longoria C; Cao G; DeLisser HM; Savani RC
    Matrix Biol; 2019 May; 78-79():255-271. PubMed ID: 30098420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients.
    Tarullo SE; He Y; Daughters C; Knutson TP; Henzler CM; Price MA; Shanley R; Witschen P; Tolg C; Kaspar RE; Hallstrom C; Gittsovich L; Sulciner ML; Zhang X; Forster CL; Lange CA; Shats O; Desler M; Cowan KH; Yee D; Schwertfeger KL; Turley EA; McCarthy JB; Nelson AC
    J Pathol; 2023 Jul; 260(3):289-303. PubMed ID: 37186300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
    Song JM; Molla K; Anandharaj A; Cornax I; O Sullivan MG; Kirtane AR; Panyam J; Kassie F
    Oncotarget; 2017 Apr; 8(16):26927-26940. PubMed ID: 28460475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.
    Leng Y; Abdullah A; Wendt MK; Calve S
    Matrix Biol; 2019 May; 78-79():236-254. PubMed ID: 30130585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line).
    Shad PM; Karizi SZ; Javan RS; Mirzaie A; Noorbazargan H; Akbarzadeh I; Rezaie H
    Toxicol In Vitro; 2020 Jun; 65():104756. PubMed ID: 31884114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
    Niedworok C; Kretschmer I; Röck K; Vom Dorp F; Szarvas T; Heß J; Freudenberger T; Melchior-Becker A; Rübben H; Fischer JW
    PLoS One; 2013; 8(9):e75681. PubMed ID: 24069434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery.
    Yang C; Wang X; Yao X; Zhang Y; Wu W; Jiang X
    J Control Release; 2015 May; 205():206-17. PubMed ID: 25665867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsive hyaluronic acid-gold cluster hybrid nanogel theranostic systems.
    Lin Y; Li C; Liu A; Zhen X; Gao J; Wu W; Cai W; Jiang X
    Biomater Sci; 2021 Feb; 9(4):1363-1373. PubMed ID: 33367388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels.
    Gurski LA; Xu X; Labrada LN; Nguyen NT; Xiao L; van Golen KL; Jia X; Farach-Carson MC
    PLoS One; 2012; 7(11):e50075. PubMed ID: 23166824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.